Long-term Safety and Efficacy Follow-up of BIIB111 for the Treatment of Choroideremia and BIIB112 for the Treatment of X-Linked Retinitis Pigmentosa
This research study is checking the long-term safety and how well two different treatments, called BIIB111 and BIIB112, work for rare genetic eye conditions. BIIB111 is for Choroideremia (CHM) and BIIB112 is for X-Linked Retinitis Pigmentosa (XLRP). Both conditions can lead to vision loss. This study is specifically for adult men who have already been treated with BIIB111 or BIIB112 in an earlier study. Researchers want to see how these treatments continue to affect vision and overall health over a longer period. Some participants with CHM who were in a previous study but didn't receive the treatment may also be included for comparison.
Auf einen Blick
Worum geht es in dieser Studie?
This research study is about two rare eye conditions: Choroideremia (CHM) and X-Linked Retinitis Pigmentosa (XLRP). Both of these conditions are genetic, meaning they run in families, and can cause progressive vision loss. Scientists are continuing to study potential treatments for these conditions, called BIIB111 for CHM and BIIB112 for XLRP.
This particular study is a follow-up, which means it’s looking at what happens to people over a longer period of time after they’ve already received one of these treatments. The main goal is to understand how safe these treatments are in the long run and how well they continue to help with vision. This is important because the effects of treatments for long-term conditions need to be carefully monitored.
The study involves people who have already taken part in an earlier study where they received BIIB111 or BIIB112. They will be compared with a small group of people with CHM who were part of an earlier study but didn't receive the treatment. This comparison helps researchers understand the true long-term effects of the treatments. The information gathered from this study will help us learn more about how to best manage and treat these serious eye conditions in the future.
Wichtige Erkenntnisse
- This is a follow-up study for men previously treated for Choroideremia (CHM) or X-Linked Retinitis Pigmentosa (XLRP).
- It aims to track the long-term safety and effectiveness of treatments BIIB111 and BIIB112.
- Participants must be 18 years or older and have received the study treatment in a prior trial.
- The study involves ongoing eye checks and general health assessments.
- Information gathered will help improve future treatments for these rare eye conditions.
- Sie können jederzeit von der Studie zurücktreten.
Wer könnte berechtigt sein?
This study is looking for adult men who are 18 years old or older. If you have **Choroideremia (CHM)**, you can join if you've already been part of another study where you received the BIIB111 treatment and that study has now ended. There will also be a small group of men with CHM joining who were in a previous study but did not receive the treatment.
If you have **X-Linked Retinitis Pigmentosa (XLRP)**, you can join if you've already received the BIIB112 treatment in a previous study and that study has now ended.
You should also be in good general health. The main reason someone might not be able to join is if the study doctor or sponsor believes it wouldn't be good for your health or well-being to take part. There might be other specific rules not listed here, so it’s always best to discuss with the study team.
Könnte diese Studie für Sie geeignet sein?
Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.
- Sind Sie 18 Jahre alt oder älter?
- Sind Sie männlich?
- Have you been diagnosed with Choroideremia (CHM) or X-Linked Retinitis Pigmentosa (XLRP)?
- If you have CHM, did you previously receive BIIB111 in an earlier study?
- If you have XLRP, did you previously receive BIIB112 in an earlier study?
Was beinhaltet die Teilnahme?
If you decide to take part in this study, you would be invited for regular check-ups at a clinic. These visits will typically involve eye tests to measure your vision and monitor the health of your eyes. They will also include general health checks and blood tests to make sure the treatment is safe for you over time. You will continue to receive the BIIB111 or BIIB112 treatment as planned. The total length of your participation would depend on the study's design, but it is focused on long-term follow-up; you would be informed about the expected duration. The study team will explain everything in detail, including how often you'd need to visit and what each visit would involve.
Potenzielle Risiken und Vorteile
Standorte (25)
- UCLA - Jules Stein Eye InstituteVerifizierte PostleitzahlLos Angeles, Vereinigte Staaten
- Vitreo Retinal Associates PA - The Millennium CenterVerifizierte PostleitzahlGainesville, Vereinigte Staaten
- Universität von MiamiVerifizierte PostleitzahlMiami, Vereinigte Staaten
- Johns Hopkins HospitalVerifizierte PostleitzahlBaltimore, Vereinigte Staaten
- MEEI Massachusets Eye and Ear InfirmaryVerifizierte PostleitzahlBoston, Vereinigte Staaten
- Columbia University Medical CenterVerifizierte PostleitzahlNew York, Vereinigte Staaten
- Cincinnati Eye Institute - Blue AshVerifizierte PostleitzahlCincinnati, Vereinigte Staaten
- OHSU - Casey Eye InstituteVerifizierte PostleitzahlPortland, Vereinigte Staaten
- Retina Foundation of the SouthwestVerifizierte PostleitzahlDallas, Vereinigte Staaten
- University of Wisconsin School of MedicineVerifizierte PostleitzahlMadison, Vereinigte Staaten
- Instituto Genetica OcularVerifizierte PostleitzahlSão Paulo, Brazil
- The Northern Alberta Clinical Trials and Research CentreVerifizierte PostleitzahlEdmonton, Kanada
Häufige Fragen
What is Choroideremia (CHM)?
CHM is a rare, inherited eye disease that causes progressive vision loss, primarily in men, leading to blindness.
What is X-Linked Retinitis Pigmentosa (XLRP)?
XLRP is a genetic eye condition that also primarily affects men, causing the light-sensing cells in the retina to break down over time, leading to vision loss.
What does 'sub-retinal injection' mean?
This is a way of delivering medicine by injecting it directly into the space just under the retina, the light-sensitive tissue at the back of your eye.
Why are only men eligible for this study?
CHM and XLRP are 'X-linked' conditions, meaning they are primarily passed down and affect males, which is why this study focuses on male participants.
What does 'long-term safety and efficacy' mean?
It means the study is checking how safe the treatments are and how well they work over a longer period, not just for a few months.
Wie Sie mehr erfahren können
Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.
Interessiert daran, teilzunehmen?
Diskussion
Community-Diskussion
Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.